VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31

Vistagen Therapeutics, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.20+0.00 (+1.55%)

Close on Oct 19, 2026

Market cap: $8.73M
P/E (TTM): –
Dividend yield: –

Vistagen Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31	FY 2016 2016-03-31	FY 2015 2015-03-31	FY 2014 2014-03-31	FY 2013 2013-03-31	FY 2012 2012-03-31	FY 2011 2011-03-31	FY 2010 2010-03-31	FY 2009 2009-03-31	FY 2008 2008-03-31	FY 2007 2007-03-31
Cash & Equivalents	31	67	119	17	68	103	1.36	13	10	2.92	0.43	0.07	–	0.64	0.08	0.14	0.20	–	–	–
Short-Term Investments	15	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	45	81	119	17	68	103	1.36	13	10	2.92	0.43	0.07	–	0.64	0.08	0.14	0.20	–	–	–
Receivables	–	–	–	–	–	–	–	–	–	–	0	–	–	–	0.11	0.04	–	–	–	–
Prepaid Expenses & Other	1.54	1.59	1.51	0.80	2.75	0.88	0.23	0.23	0.64	0.46	0.43	0.04	0.04	0.04	0.03	0.02	–	–	–	–
Total Current Assets	47	82	121	18	71	104	1.58	14	11	3.38	0.86	0.11	0.04	0.04	0.67	0.20	–	–	–	–
Property, Plant & Equipment	0.43	0.48	0.44	0.51	0.41	0.37	0.21	0.31	0.21	0.29	0.09	0.12	0.18	0.18	0.18	0.09	–	–	–	–
Gross Property, Plant & Equipment	1.50	1.88	1.69	1.70	1.68	1.52	1.25	1.25	1.05	1.05	0.80	0.78	0.78	0.73	0.60	–	–	–	–	–
Accumulated Depreciation	-1.07	-1.40	-1.25	-1.19	-1.27	-1.15	-1.04	-0.93	-0.84	-0.76	-0.71	-0.67	0.61	0.55	0.53	–	–	–	–	–
Machinery & Equipment	–	–	–	–	–	–	–	–	–	–	–	0.65	0.65	0.65	0.52	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.80	1.34	1.82	2.26	2.66	3.22	3.58	0	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.39	0.45	0.73	–	–	–	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.03	0.03	–	–	–	–
Total Assets	49	84	124	21	75	108	5.77	14	11	3.71	0.99	0.27	0.26	0.26	0.88	0.32	–	–	–	–
Accounts Payable	1.54	0.65	1.55	2.47	2.76	0.84	1.84	1.06	1.20	0.87	0.94	2.25	2.44	2.44	1.35	1.77	–	–	–	–
Accrued Expenses	8.76	8.81	2.24	0.80	1.33	1.56	0.56	1.69	0.21	0.44	0.81	1.21	0.63	0.63	0.34	1.42	–	–	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	-1.51	1.44	–	–	–	–	–	–	–
Current Debt	–	–	–	–	–	–	–	–	–	–	–	–	1.44	–	–	–	–	–	–	–
Current Portion of Leases	0.70	0.56	0.55	0.49	0.43	0.36	0.31	0	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	1.71	2.59	0.79	0.71	1.24	1.42	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	13	13	5.12	4.57	5.77	4.19	28	2.80	1.46	1.37	1.79	17	5.21	5.21	2.41	11	–	–	–	–
Long-Term Debt	–	–	–	–	–	–	0	–	0	0	0.03	0.04	–	–	–	–	–	–	–	–
Long-Term Leases	0.25	0.95	1.57	2.12	2.61	3.35	3.72	0	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.95	1.51	2.12	2.61	3.04	3.72	4.03	0	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.42	–	–	–	–
Total Liabilities	13	14	9.37	9.01	9.93	16	12	6.94	4.36	3.10	3.97	21	13	13	13	19	–	–	–	–
Total Debt	–	–	–	–	–	–	0	–	0	0	0.03	0.04	1.44	–	–	–	–	–	–	–
Preferred Stock	0	0	0	0	0	–	–	–	–	–	–	0.00	0.00	0.00	0.00	15	–	–	–	–
Common Stock	0.04	0.03	0.03	0.01	0.01	0.18	0.05	0.04	0.02	0.01	0.00	0.00	0.00	0.00	0.02	0.01	–	–	–	–
Additional Paid-In Capital	517	482	474	343	336	316	200	192	167	147	133	68	62	62	59	9.87	–	–	–	–
Retained Earnings	-477	-408	-356	-327	-268	-220	-202	-181	-157	-142	-132	-85	-71	-71	-68	-43	–	–	–	–
Treasury Stock	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	-3.97	0	–	–	–	–
Comprehensive Income & Other	0.00	0.01	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	36	70	114	12	65	92	-5.73	7.08	6.92	0.62	-2.98	-21	-13	-13	-5.71	-33	-26	-27	-22	-17
Total Equity	36	70	114	12	65	92	-5.73	7.08	6.92	0.62	-2.98	-21	-13	-13	-5.71	-33	-26	-27	-22	-17
Total Liabilities & Equity	49	84	124	21	75	108	5.77	14	11	3.71	0.99	0.27	0.26	0.26	0.88	0.32	–	–	–	–
Shares Outstanding(shares)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.03	0.01	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -2784.3%
Net margin: -2702.6%
Return on equity, FY2026: -131.6%

Financial strength

Current ratio: 3.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 151.8%

Valuation

P/E ratio: –
Price to sales: 3.49
Price to book: 0.36
Dividend yield: –